
Sign up to save your podcasts
Or


Salveen Richter, lead analyst for the US Biotechnology sector in Goldman Sachs Research, talks about Pfizer’s clinical-trial results for its COVID-19 vaccine and the obstacles that still lie ahead for FDA approval and widespread distribution.
Learn more about your ad choices. Visit megaphone.fm/adchoices
By Goldman Sachs4.2
912912 ratings
Salveen Richter, lead analyst for the US Biotechnology sector in Goldman Sachs Research, talks about Pfizer’s clinical-trial results for its COVID-19 vaccine and the obstacles that still lie ahead for FDA approval and widespread distribution.
Learn more about your ad choices. Visit megaphone.fm/adchoices

1,179 Listeners

2,173 Listeners

1,891 Listeners

194 Listeners

95 Listeners

797 Listeners

1,041 Listeners

83 Listeners

183 Listeners

60 Listeners

1,299 Listeners

77 Listeners

447 Listeners

29 Listeners

73 Listeners